China
Africa
Explore chapters and articles related to this topic
Drug side effects on the distal phalanx
Published in Robert Baran, Dimitris Rigopoulos, Chander Grover, Eckart Haneke, Nail Therapies, 2021
Irbesartan used to lower blood pressure of a 77-year-old patient was responsible for pain of the nail unit involving all digits 6 months after beginning of her treatment. This symptom was associated with progressive nail dystrophy leading to the clinical diagnosis of lichen planus that was confirmed histologically (Bories and Denis 2005).
Cardiovascular Drugs
Published in Radhwan Nidal Al-Zidan, Drugs in Pregnancy, 2020
Risk Summary: Irbesartan is contraindicated during the 2nd and 3rd Trimesters because the pregnancy experience in humans showed a profound potentiality of teratogenicity and severe fetal toxicity associated with its use during this period.
Compatibility of commonly used drugs in lactation
Published in Amy Brown, Wendy Jones, A Guide to Supporting Breastfeeding for the Medical Profession, 2019
No evidence of safety from trials. Candestartan – bioavailability 14%, PPB > 99%.Irbesartan – oral bioavailability 60–80%, PPB 90%.Losartan – oral bioavailability 33%, PPB 99.8%.Valsartan– oral bioavailability 23%, PPB 95%.
The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study
Published in Biomarkers, 2019
Ryoko Umebayashi, Haruhito A. Uchida, Yuka Okuyama, Yuki Kakio, Yoshihisa Hanayama, Kenichi Shikata, Jun Wada
The present study was designed to compare the anti-inflammatory and anti-oxidative stress effects of irbesartan to that of other ARBs. Since inflammatory markers are affected by hypertension, blood pressures levels should be controlled at the same level in both medication groups. In the present study, blood pressures were successfully lowered in both groups without any adverse effects such as excessive blood pressure lowering, excessive renal function decline and oedemas; this result implies there are no significant differences in blood lowering effect among these ARBs in a clinical setting. Therefore, the anti-inflammatory and anti-oxidative stress effects of irbesartan were compared with that of the other ARBs independent of the degree of blood pressure reduction in this study. Our major findings are that (i) switching ARBs to irbesartan did not affect anti-inflammatory and anti-oxidative stress markers in clinical settings; (ii) irbesartan reduced albumin excretion without a renal function decline; (iii) irbesartan reduced total cholesterol and LDL-cholesterol. These results provide knowledge about the characteristics of irbesartan in clinical settings, leading to appropriate selection of ARBs for hypertension treatment.
Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats
Published in Clinical and Experimental Hypertension, 2018
Whaley-Connell (22) found that renin inhibition improves albuminuria comparable to ANG type 1 receptor (AT1R) blockade (ARB) in the double transgenic Ren2 rat, which manifests hypertension, proteinuria, and oxidative stress as well as nephrogenic changes. Abnormalities were attenuated to a similar extent with both aliskiren and irbesartan treatments. Despite the fact that the dose of irbesartan used caused a greater reduction in systolic blood pressure than aliskerin treatment (P < 0.05), the effects on proteinuria, nephrin, and oxidative stress were similar between the two treatments. These results highlight both the importance of pressor-related reductions on nephrogenic changes and proteinuria as well as renin–angiotensin system (RAS)-mediated oxidant stress that were largely comparable between ARB and renin inhibition treatment.
Pharmacokinetic study on the interaction between succinic acid and irbesartan in rats and its potential mechanism
Published in Pharmaceutical Biology, 2021
Yongpeng Wang, Ruping Rui, Xiaoyan Zhang, Bin Sun
Irbesartan is an angiotensin III receptor antagonist, which is applied in the clinical treatment of hypertension, metabolic syndrome, and cardiac disease (Markham et al. 2000; Vignier et al. 2014). CYPC2C9 was reported to be involved in the biotransformation of irbesartan, and the interactions of irbesartan with other drugs metabolized by CYP2C9 or affect the activity of CYP2C9 have been widely reported (Bourrie et al. 1999; Marino and Vachharajani 2001; Yang et al. 2016). The similar indications of succinic acid and irbesartan make them possible to appear in the same medical treatment. The interaction between these two drugs is of great importance, which might result in adverse effects on the therapeutic efficacy.